Establishment Labs Hldgs Inc Stock Price, News & Analysis

Establishment Labs (NASDAQ: ESTA) reported Q3 2025 results for the quarter ended September 30, 2025: revenue $53.8M (+33.8% YoY) and gross margin 70.1% versus 63.9% a year ago. Q3 net loss narrowed to $11.1M and Adjusted EBITDA was positive $1.2M. Cash was $70.6M at quarter-end; cash decreased $19.7M year-to-date. Company raised 2025 revenue outlook to above $210M and reiterated goal to reach cash flow positive next year while targeting ~20% US breast augmentation market share and higher US Motiva sales.

Establishment Labs (NASDAQ: ESTA) will release third quarter 2025 financial results for the period ended September 30, 2025 before market open on Wednesday, November 5, 2025, and will host a conference call at 8:30 AM ET the same day.

Dial-in numbers: (877) 407-8037 (U.S./Canada) or +1 (201) 689-8037 (International); conference ID 13750830. A live and archived webcast will be available in the Investor Relations section at www.establishmentlabs.com.

Company overview: a global medical device company with products in breast aesthetics and reconstruction sold in over 90 countries, >4 million Motiva devices delivered since 2010, multiple IRB-approved pivotal studies (GEM, Zenº, Motiva Flora), >200 patent applications, and two ISO13485:2016 and FDA 21 CFR 820–compliant manufacturing sites in Costa Rica.

Establishment Labs (NASDAQ: ESTA) highlighted publication of a 3-year, 100-patient prospective study of Mia Femtech in Aesthetic Surgery Journal showing very low complication rates and no reports of capsular contracture (Baker III/IV), implant rupture, nipple/breast sensitivity loss, infection, seroma, rippling, hematoma, or BIA-ALCL; 3-year reoperation rate was 1%.

Patient follow-up was 93%, patient satisfaction rose 87% at 3 years, and 90% of surgeons were very satisfied. The company expects the minimally invasive platform to generate at least $30 million in 2026. Mia Femtech and Ergonomix2 Diamond implants are available internationally but not cleared for sale in the United States; Preservé is in limited U.S. release.

Establishment Labs (NASDAQ: ESTA) released its 2025 Post-Market Surveillance (PMS) Report on October 9, 2025, summarizing 15 years of real-world Motiva implant data.

The report aggregates peer-reviewed studies, global registries, warranty and claims data, and regulatory-study results, and reports less than 1% device-related complications leading to reoperations across sources. The company cites >15 years of consistent outcomes, >4 million Motiva devices delivered since 2010, and an expectation of approximately 400,000 additional patients next year. The PMS is published annually and is available on the company website.

Establishment Labs (NASDAQ: ESTA) reported Q2 2025 financial results with revenue of $51.3 million, up 16.3% year-over-year. The company increased its 2025 revenue guidance to $208-212 million, representing 25-28% growth. Q2 highlights include $10.3 million in US Motiva sales and improved gross margin of 68.8%.

The company reported a Q2 operating loss of $14.1 million and adjusted EBITDA loss of $8.5 million. Cash balance stood at $54.6 million with an additional $25 million available under credit line. Management expects to achieve positive EBITDA in 2025 and become cash flow positive in 2026.

Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, will release its Q2 2025 financial results on August 7, 2025, before market open. The company will host a conference call at 8:30 AM ET to discuss the results.

The company has delivered over 4 million Motiva® devices to surgeons since 2010 and operates in more than 90 countries. Their innovative product portfolio includes Mia Femtech®, Preservé™, GEM®, Motiva Flora® tissue expander, and Zensor™ RFID technology. The company maintains two FDA-compliant manufacturing facilities in Costa Rica and holds over 200 patent applications across 20 patent families.

Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company specializing in breast aesthetics and reconstruction, will host an analyst and investor event in New York City on June 12, 2025, at 1pm ET. The company has delivered over 4 million Motiva devices to surgeons since 2010 and operates in over 90 countries. Their product portfolio includes innovative solutions like Mia Femtech, Preservé, GEM, Motiva Flora tissue expander, and Zensor RFID technology. The company's technologies are backed by over 200 patent applications across 20 patent families and more than 100 scientific studies. Manufacturing occurs at two FDA-compliant facilities in Costa Rica.

Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health and breast aesthetics, announced its participation in the Jefferies Global Healthcare Conference. CEO Peter Caldini and CFO Raj Denhoy will present on June 4, 2025, at 7:35 a.m. ET. The company has delivered over 4 million Motiva devices since 2010 and operates in 90+ countries. Their product portfolio includes Mia Femtech, Preservé, GEM, Motiva Flora tissue expander, and Zensor RFID technology. The company manufactures at two FDA-compliant facilities in Costa Rica and holds over 200 patent applications across 20 patent families, supported by 100+ scientific studies.

Establishment Labs Holdings (NASDAQ: ESTA) has appointed Peter Caldini as permanent Chief Executive Officer effective May 7, 2025. Caldini, who has served as Interim CEO since March 1, 2025, following the retirement of Founder Juan José Chacón-Quirós, brings extensive operational, commercial, and financial expertise. The company aims to achieve EBITDA positivity in 2025 and cash flow positivity in 2026. Caldini previously served as President at Establishment Labs and held executive positions at Acreage Holdings, Pfizer Consumer Healthcare, and Bayer Consumer Healthcare. Establishment Labs, a global medical technology company focused on breast aesthetics and reconstruction, has delivered over 4 million Motiva devices since 2010 and operates in over 90 countries with manufacturing facilities in Costa Rica.